10.16.07
Johnson & Johnson
3Q Revenues: $15 billion (+13%)
3Q Earnings: $2.5 billion (-8%)
YTD Revenues: $45.1 billion (+14%)
YTD Earnings: $8.2 billion (-8%)
Comments: Worldwide pharmaceutical sales were $6.1 billion in the quarter, up 4%. Growth reflects the strong performance of Topamax, Remicade, and antipsychotic franchise, which includes Risperdal, Risperdal Consta and Invega. Earnings for the quarter include an after-tax restructuring charge of $528 million associated with a cost improvement program.
3Q Revenues: $15 billion (+13%)
3Q Earnings: $2.5 billion (-8%)
YTD Revenues: $45.1 billion (+14%)
YTD Earnings: $8.2 billion (-8%)
Comments: Worldwide pharmaceutical sales were $6.1 billion in the quarter, up 4%. Growth reflects the strong performance of Topamax, Remicade, and antipsychotic franchise, which includes Risperdal, Risperdal Consta and Invega. Earnings for the quarter include an after-tax restructuring charge of $528 million associated with a cost improvement program.